Agios Pharmaceuticals has officially terminated the clinical development of tebapivat, an investigational oral PKR activator intended for the treatment of sickle cell disease (SCD), after mid-stage clinical data failed to demonstrate a competitive advantage over existing therapies. The decision, announced following a review of Phase 2 results, marks a strategic pivot for the Cambridge, Massachusetts-based biotechnology company as it consolidates its resources toward its lead candidate, mitapivat. While tebapivat showed some efficacy in improving hemoglobin levels, the data indicated a lack of dose-dependent response and insufficient differentiation from both Agios’s own approved drugs and rival candidates currently in late-stage development.
The discontinuation of tebapivat comes at a critical juncture for the sickle cell disease market, which has recently been characterized by both landmark gene therapy approvals and high-profile drug withdrawals. Agios had positioned tebapivat as a potential "best-in-class" successor to mitapivat, primarily due to its once-daily dosing schedule compared to mitapivat’s twice-daily regimen. However, the failure to establish a superior clinical profile has led the company to prioritize the regulatory path for mitapivat, which is currently under Priority Review by the U.S. Food and Drug Administration (FDA) for the same indication.
Understanding the Mechanism: The Role of Pyruvate Kinase Activation
To understand the failure of tebapivat, it is necessary to examine the underlying science of sickle cell disease and the role of the enzyme pyruvate kinase (PK). Sickle cell disease is a hereditary blood disorder caused by a mutation in the beta-globin gene, leading to the production of abnormal hemoglobin S. When oxygen levels are low, this abnormal hemoglobin polymerizes, causing red blood cells to take on a rigid, sickle-like shape. These cells are prone to hemolysis (destruction) and can block blood flow, leading to vaso-occlusive crises (VOCs), chronic pain, and organ damage.
Tebapivat was designed as a small-molecule activator of the R-isoform of pyruvate kinase (PKR), which is the predominant form of the enzyme found in red blood cells. By binding to and activating PKR, the drug aimed to achieve two primary metabolic goals:
- Increasing Adenosine Triphosphate (ATP): Higher ATP levels improve the structural integrity and deformability of red blood cells, helping them navigate narrow capillaries without sickling.
- Decreasing 2,3-Diphosphoglycerate (2,3-DPG): Lowering levels of this metabolite increases the affinity of hemoglobin for oxygen. Since sickling occurs primarily when hemoglobin is deoxygenated, keeping hemoglobin in an oxygenated state prevents the polymerization process.
While this mechanism of action remains valid—and is the basis for the success of mitapivat—the clinical data for tebapivat did not suggest that it could outperform existing options or justify the significant investment required for Phase 3 trials.
Analysis of Phase 2 Results and Lack of Differentiation
The decision to halt tebapivat was driven by preliminary results from a Phase 2 study involving patients with sickle cell disease. According to Agios, while the drug did lead to improvements in hemoglobin levels and markers of hemolysis, the response was not dose-dependent. In drug development, a dose-dependent response—where higher doses yield progressively greater efficacy or predictable changes—is a key indicator of a drug’s reliability and therapeutic window.
Furthermore, the results did not stand out against the Phase 3 data already established by mitapivat. Mitapivat, marketed as Pyrukynd for other indications, has already demonstrated robust efficacy in increasing hemoglobin and reducing VOCs in sickle cell patients. From a commercial and clinical perspective, bringing a second, similar drug to market requires a clear "value add," such as significantly higher efficacy or a drastically improved safety profile. Tebapivat failed to meet this threshold.
The competitive landscape also played a major role in the decision. Specifically, Novo Nordisk’s etavopivat, another PKR activator, reported strong Phase 3 results in April from its HIBISCUS trial. Etavopivat demonstrated substantial reductions in VOC events and significant increases in hemoglobin. For Agios to compete in this space, tebapivat needed to show a profile that was at least equal to, if not better than, etavopivat. When the Phase 2 data suggested tebapivat was merely "undifferentiated," the path to market leadership became increasingly narrow.
The Broader Context: A Volatile Year for Sickle Cell Disease Research
Agios’s withdrawal of tebapivat is the latest in a series of setbacks for the sickle cell community. Over the past 24 months, the therapeutic landscape has faced several high-profile challenges:
- Pfizer’s Withdrawal of Oxbryta: In late 2024, Pfizer voluntarily withdrew Oxbryta (voxelotor) from global markets. The decision followed post-marketing data suggesting an increased risk of complications and a higher death rate in the treatment group compared to the placebo group. This left a massive void in the market for oral therapies that improve hemoglobin levels.
- Fulcrum Therapeutics’ Discontinuation: In June 2026, Fulcrum Therapeutics stopped the development of pociredir, a PRC2 inhibitor, after the FDA raised concerns regarding the potential cancer risk associated with the entire class of drugs in the context of sickle cell disease.
- Pfizer’s Inclacumab Failure: A Phase 3 study for Pfizer’s inclacumab, designed to treat vaso-occlusive crises, failed to meet its primary endpoints in 2025, further narrowing the pipeline of non-genetic treatments.
Against this backdrop of industry-wide failures, the pressure on Agios to deliver a "clean" and highly effective drug was immense. By stopping tebapivat now, the company avoids the high costs of a Phase 3 program that might have ultimately failed to gain market share or regulatory approval in an increasingly scrutinized environment.
Strategic Pivot to Mitapivat and Regulatory Milestones
With tebapivat sidelined, Agios is doubling down on mitapivat. The drug is already a cornerstone of the company’s portfolio, having received FDA approval for the treatment of hemolytic anemia in adults with PK deficiency in 2022. More recently, in December 2025, the FDA approved the molecule under the brand name Aqvesme for the treatment of anemia in adults with alpha- and beta-thalassemia.
The company is now aggressively pursuing a label expansion for mitapivat to include sickle cell disease. Two weeks ago, the FDA accepted Agios’s Supplemental New Drug Application (sNDA) and granted it Priority Review. The agency has set a Prescription Drug User Fee Act (PDUFA) target action date of November 1.
Sarah Gheuens, M.D., Ph.D., Chief Medical Officer and Head of R&D at Agios, emphasized that the company’s focus remains steadfast on mitapivat. "We remain focused on mitapivat, our foundational PK activator, which is under FDA Priority Review in sickle cell disease with an expected U.S. approval later this year," Gheuens stated. She noted that the "extensive clinical experience" generated with mitapivat across multiple indications provides a level of confidence that tebapivat could not match at its current stage of development.
Financial Outlook and Market Reaction
Wall Street analysts have viewed the discontinuation of tebapivat as a pragmatic, though defensive, move. Andrew Berens, an analyst at Leerink Partners, noted in a research report that his firm had not included tebapivat in its financial models for Agios, meaning the cancellation does not result in a downgrade. However, Berens highlighted that tebapivat was the company’s primary vehicle for challenging Novo Nordisk’s once-daily PKR activator.
Without tebapivat, the burden of commercial success falls entirely on mitapivat. While mitapivat is a "first-in-class" activator, its twice-daily dosing may be a slight disadvantage compared to Novo Nordisk’s once-daily etavopivat, provided the latter reaches the market. Agios will need to rely on its established safety record and the "first-to-market" advantage in the PKR activator space for sickle cell disease.
The financial health of Agios remains stable, bolstered by the sale of its oncology business to Servier in 2021 for $1.8 billion upfront. This capital has allowed the company to focus exclusively on genetically defined rare diseases. By cutting tebapivat, Agios can reallocate R&D funds toward other pipeline candidates, such as those targeting lower-profile rare hemolytic anemias or other metabolic disorders.
Chronology of Agios’s PKR Activator Development
- February 2022: FDA approves mitapivat (Pyrukynd) for pyruvate kinase deficiency.
- September 2022: Novo Nordisk acquires Forma Therapeutics for $1.1 billion, gaining etavopivat, a direct competitor to Agios’s PKR portfolio.
- December 2025: FDA approves mitapivat (Aqvesme) for alpha- and beta-thalassemia.
- April 2026: Novo Nordisk announces successful Phase 3 results for etavopivat in sickle cell disease.
- June 2026: Agios submits sNDA for mitapivat in sickle cell disease.
- July 7, 2026: FDA grants Priority Review to mitapivat for sickle cell disease with a November 1 target date.
- July 21, 2026: Agios announces the discontinuation of tebapivat following Phase 2 data review.
Implications for the Sickle Cell Community
For patients and clinicians, the discontinuation of tebapivat is a reminder of the difficulties inherent in treating sickle cell disease. While the arrival of gene therapies like Casgevy (Vertex/CRISPR) and Lyfgenia (bluebird bio) has offered the hope of "functional cures," these treatments are prohibitively expensive and require grueling bone marrow transplants. There remains a desperate need for accessible, oral small molecules that can manage the disease on a daily basis.
If mitapivat receives approval on November 1, it will become a vital tool for hematologists, particularly in the wake of the Oxbryta withdrawal. The failure of tebapivat does not diminish the potential of the PKR activation class; rather, it reinforces the strength of mitapivat as the primary candidate for this mechanism.
As the industry moves toward the end of 2026, all eyes will be on the FDA’s decision regarding mitapivat. For Agios, the stakes are high: the company must prove that its "foundational" molecule can fill the gap left by failed competitors and provide a reliable, long-term therapy for a patient population that has seen too many promising leads end in disappointment.
